|
May 15
|
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
|
|
May 15
|
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ...
|
|
May 15
|
Q1 2024 Ocugen Inc Earnings Call
|
|
May 14
|
Ocugen Provides Business Update with First Quarter 2024 Financial Results
|
|
May 10
|
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
|
|
May 10
|
Ocugen to Present at May 2024 Investor Conferences
|
|
May 8
|
Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028
|
|
May 3
|
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
|
|
May 2
|
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
|
|
Apr 29
|
Can Ocugen Stock Keep Churning Higher?
|
|
Apr 29
|
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
|
|
Apr 26
|
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
|
|
Apr 26
|
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
|
|
Apr 26
|
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
|
|
Apr 19
|
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
|
|
Apr 12
|
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
|
|
Apr 10
|
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
|
|
Apr 8
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
|
Apr 8
|
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
|
|
Apr 5
|
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
|